AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
37.17
+0.14 (+0.38%)
At close: 4:04PM EDT
Stock chart is not supported by your current browser
Previous Close37.03
Open36.99
Bid0.00 x 0
Ask0.00 x 0
Day's Range36.96 - 37.37
52 Week Range28.43 - 37.37
Volume2,004,825
Avg. Volume3,662,049
Market Cap94.933B
Beta0.54
PE Ratio (TTM)33.58
EPS (TTM)1.11
Earnings DateN/A
Forward Dividend & Yield1.40 (4.01%)
Ex-Dividend Date2018-02-15
1y Target Est39.09
Trade prices are not sourced from all markets
  • Tesla, Facebook and AstraZeneca are the Yahoo Finance charts of the day.
    Yahoo Finance Video20 days ago

    Tesla, Facebook and AstraZeneca are the Yahoo Finance charts of the day.

    Let's check out the Yahoo Finance charts of the day. Tesla (TSLA): Shares are up in early trade, at around 5.3%. The electric car maker reached its goal of producing 5,000 Model 3 sedans in a week, hours after the self-imposed deadline. Facebook (FB): Shares are flat here at around .26%.  Facebook revealed to Congress on Friday that it gave dozens of companies special access to user data. AstraZeneca (AZN): Shares down here at around 1.6%. The biopharmaceutical company won rapid regulatory approval for new uses of two of its important cancer drugs in Japan, adding a key market for the British drug maker.  For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • Analysts’ Recommendations for Stryker and Its Peers in July
    Market Realist2 days ago

    Analysts’ Recommendations for Stryker and Its Peers in July

    The SG&A expenses incurred by Stryker (SYK) are expected to increase 9.4% from $1.05 billion in the second quarter of 2017 to $1.15 billion in the second quarter. Total operating expenses incurred by Stryker are expected to reach $1.42 billion for the second quarter, compared with $1.49 billion for the second quarter of 2017. Analysts expect Stryker (SYK) to report net income of $549.25 million in the second quarter compared with $391.0 million in the second quarter of 2017, an increase of 40.47%.

  • What Analysts Think about AstraZeneca and Peers in July
    Market Realist2 days ago

    What Analysts Think about AstraZeneca and Peers in July

    AstraZeneca (AZN) is expected to incur research and development expenses of $1.26 billion in Q2 2018 as compared with $1.28 billion in Q2 2017, a decrease of 1.56%. AstraZeneca is expected to report net income per share of $0.04 in Q2 2018 as compared with $0.19 in Q2 2017. Four of the total six analysts covering AstraZeneca in July 2018 have given it a “buy” or higher rating.

  • What to Expect from AstraZeneca’s Second-Quarter Earnings
    Market Realist2 days ago

    What to Expect from AstraZeneca’s Second-Quarter Earnings

    AstraZeneca (AZN), the maker of key products like Lynparza, Tagrisso, Imfinzi, Brilinta, and Farxiga, is expected to report Q2 2018 earnings on July 26. AstraZeneca’s revenues are expected to increase 0.77% from $5.05 billion in Q2 2017 to $5.09 billion in Q2 2018. In fiscal 2017, AstraZeneca generated $22.46 billion in revenues.

  • Reuters2 days ago

    EU drug regulators step up work to prepare for 'no deal' Brexit

    Drug regulators across Europe are hiring extra staff and increasing their workload as the role of British experts in the EU-wide system of medicines supervision winds down ahead of Brexit. Although the UK's exit from the European Union is still eight months away, Britain has already stopped taking on new projects that will extend beyond March 29, 2019 and is preparing to hand over existing drug review work to other countries.

  • Reuters2 days ago

    EU drug regulators step up work to prepare for 'no deal' Brexit

    Drug regulators across Europe are hiring extra staff and increasing their workload as the role of British experts in the EU-wide system of medicines supervision winds down ahead of Brexit. Although the UK's exit from the European Union is still eight months away, Britain has already stopped taking on new projects that will extend beyond March 29, 2019 and is preparing to hand over existing drug review work to other countries.

  • Reuters4 days ago

    AstraZeneca to stockpile drugs as Brexit 'safety net'

    AstraZeneca (AZN.L) is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal. The move affects drugs made in Britain that could be exported to Europe and supplies in the European Union that may be headed the other way. A company spokesman said on Wednesday that AstraZeneca currently held several months of supplies of such medicines and this was being increased for products on both sides of the Channel.

  • AstraZeneca Reports Promising Data for Lynparza in Ovarian Cancer
    Market Realist9 days ago

    AstraZeneca Reports Promising Data for Lynparza in Ovarian Cancer

    On June 27, AstraZeneca (AZN) and Merck (MRK) reported positive data for their Phase 3 Lynparza trial, SOLO-1, a randomized, double-blind, placebo-controlled trial for ovarian cancer. The drug met the primary endpoint of progression-free survival in women with BRCA1-mutated advanced ovarian cancer. Lynparza is the only PARP2 inhibitor to show significant activity in a first-line maintenance setting. Based on this data, the two companies plan to initiate discussions with authorities for regulatory submissions.

  • MarketWatch9 days ago

    Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial

    Shares of the biotech company Advaxis Inc. (ADXS) surged 68% in premarket trade on Friday after the Food and Drug Administration lifted a clinical hold on the company's phase 1/2 study for a cancer drug combination. The trial is testing a combination of Advaxis' axalimogene filolisbac, a listeria-based immunotherapy, and Astrazeneca's durvalumab (AZN) for patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer.

  • ACCESSWIRE9 days ago

    Today's Research Reports on Trending Tickers: Johnson & Johnson and AstraZeneca

    NEW YORK, NY / ACCESSWIRE / July 13, 2018 / U.S. markets made it in the green on Thursday, pushed higher by rally in information technology and telecom stocks, covering continued uncertainty over trade ...

  • Moody's11 days ago

    Moody's: European pharma sector earnings poised to rise into 2019 as new drugs come to market

    An emerging wave of blockbuster drugs will accelerate European pharmaceutical companies' revenue growth into 2019, says Moody's Investors Service in a report published today. The rating agency's report is an update to the markets and does not constitute a rating action.

  • Highmark, pharmaceutical company reach deal on diabetes drug
    American City Business Journals12 days ago

    Highmark, pharmaceutical company reach deal on diabetes drug

    Jardiance is prescribed for people with latter stages of Type 2 diabetes that also have cardiovascular disease.

  • InvestorPlace12 days ago

    Biogen Is the Right Alzheimer’s Stock … At the Wrong Time

    On Friday, Biogen (NASDAQ:BIIB) shares soared on news that one of its Alzheimer’s drug trials was showing tremendous promise. Specifically, BIIB stock jumped nearly 20% after an update on BAN-2401, a phase 2 drug that showed a statistically significant slowdown in the memory loss associated with Alzheimer’s. BAN-2401, an antibody that takes aim at the amyloid plaque in the brain that’s thought to be a key cause of Alzheimer’s, was cast into a questionable light late last year.

  • The Wall Street Journal16 days ago

    [$$] Difficult Conversation: When the Harasser Is a Client

    At many companies, client relationships are the most difficult to police – and the most important to protect. A former vice president at market-data firm Research Now SSI alleged in a lawsuit filed in April that a senior executive from the airline Virgin America, Stuart Dinnis, began kissing and groping her without warning in a hotel elevator late at night during a 2016 travel-industry conference. Earlier that day, she and her boss had discussed Mr. Dinnis, then Virgin America’s director of loyalty, as an important client to cultivate during the conference.

  • Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
    Zacks16 days ago

    Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs

    Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.

  • Hitting cancer early: AstraZeneca's bid to outmaneuver rivals
    Reuters16 days ago

    Hitting cancer early: AstraZeneca's bid to outmaneuver rivals

    AstraZeneca (AZN.L) suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Soriot and his team are increasingly confident that while AstraZeneca may have lost one part of the battle for cancer market dominance, it can still win elsewhere by targeting tumors before they have spread around the body. The idea that immunotherapy may actually work best in less sick patients is logical, since the immune system's natural role is to destroy nascent tumors.

  • Reuters16 days ago

    Hitting cancer early: AstraZeneca's bid to outmanoeuvre rivals

    AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Soriot and his team are increasingly confident that while AstraZeneca may have lost one part of the battle for cancer market dominance, it can still win elsewhere by targeting tumours before they have spread around the body. The idea that immunotherapy may actually work best in less sick patients is logical, since the immune system's natural role is to destroy nascent tumours.

  • AstraZeneca’s Imfinzi and Lynparza Receive Approval in Japan
    Market Realist19 days ago

    AstraZeneca’s Imfinzi and Lynparza Receive Approval in Japan

    AstraZeneca (AZN) received two key regulatory approvals this week in Japan. On July 2, its immunotherapy drug Imfinzi was approved by Japan’s Ministry of Health, Labour and Welfare for lung cancer patients whose disease was inoperable and has advanced locally but has not widely spread throughout the body. It has been approved as a maintenance therapy after definitive chemoradiation therapy (or CRT).

  • AstraZeneca's Two New Cancer Drugs Get Approval in Japan
    Zacks19 days ago

    AstraZeneca's Two New Cancer Drugs Get Approval in Japan

    AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication and Imfinzi for an early-stage lung cancer indication.

  • Tesla shares soar after reaching Model 3 production goal, Facebook shares flat and AstraZeneca shares are down
    Yahoo Finance20 days ago

    Tesla shares soar after reaching Model 3 production goal, Facebook shares flat and AstraZeneca shares are down

    Tesla, Facebook and AstraZeneca are the Yahoo Finance charts of the day.

  • AstraZeneca wins speedy approvals for cancer drugs in Japan
    Reuters20 days ago

    AstraZeneca wins speedy approvals for cancer drugs in Japan

    LONDON (Reuters) - AstraZeneca (AZN.L) has won rapid regulatory approval for new uses of two of its important cancer drugs in Japan, less than six months after the first global approvals in Western markets. ...

  • Reuters20 days ago

    AstraZeneca wins speedy approvals for cancer drugs in Japan

    AstraZeneca has won rapid regulatory approval for new uses of two of its important cancer drugs in Japan, less than six months after the first global approvals in Western markets. The decisions by the ...

  • ACCESSWIRE23 days ago

    Blog Exposure – AstraZeneca’s LYNPARZA(R) Reports Encouraging Results from Phase-III 1st-Line SOLO-1 Trial for Advanced Ovarian Cancer

    LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want access to our free research report on AstraZeneca PLC (NYSE: AZN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AZN as the Company's latest news hit the wire. On June 27, 2018, the Company and Merck & Co., Inc. (NYSE: MRK) together announced encouraging results from the randomized, double-blinded, placebo-controlled, Phase-III SOLO-1 trial assessing LYNPARZA® (olaparib) tablets (300 mg twice daily) in BRCA-mutated (BRCAm) advanced ovarian cancer.

  • Business Wire25 days ago

    LYNPARZA® (olaparib) Significantly Delays Disease Progression in Phase III 1st-Line SOLO-1 Trial for Ovarian Cancer

    AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today announced positive results from the randomized, double-blinded, placebo-controlled, Phase III SOLO-1 trial of LYNPARZA® tablets .